WEKO3
アイテム
Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments
https://tokushima-u.repo.nii.ac.jp/records/2009208
https://tokushima-u.repo.nii.ac.jp/records/200920884b4d9b1-3203-42ef-aa6f-e76c9d030e81
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
cnr_5_1_e1402.pdf (659 KB)
|
.png)
|
| Item type | 文献 / Documents(1) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2021-09-16 | |||||||||||||||||||||||||||||
| アクセス権 | ||||||||||||||||||||||||||||||
| アクセス権 | open access | |||||||||||||||||||||||||||||
| 資源タイプ | ||||||||||||||||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||||||||||||||||
| 資源タイプ | journal article | |||||||||||||||||||||||||||||
| 出版社版DOI | ||||||||||||||||||||||||||||||
| 識別子タイプ | DOI | |||||||||||||||||||||||||||||
| 関連識別子 | https://doi.org/10.1002/cnr2.1402 | |||||||||||||||||||||||||||||
| 言語 | ja | |||||||||||||||||||||||||||||
| 関連名称 | 10.1002/cnr2.1402 | |||||||||||||||||||||||||||||
| 出版タイプ | ||||||||||||||||||||||||||||||
| 出版タイプ | VoR | |||||||||||||||||||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||||||||||||||||||||||
| タイトル | ||||||||||||||||||||||||||||||
| タイトル | Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments | |||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||
| 著者 |
ナワ, ヒデキ
× ナワ, ヒデキ
× 新村, 貴博
WEKO
1496
× 八木, 健太× 合田, 光寛
WEKO
943
× 座間味, 義人× 石澤, 啓介
WEKO
228
|
|||||||||||||||||||||||||||||
| 抄録 | ||||||||||||||||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||||||||||||||||
| 内容記述 | Background: Various cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have demonstrated promising anti-tumor effects. The Japanese Ministry of Health, Labour and Welfare has issued a warning about interstitial lung diseases as an adverse effect of CDK4/6 inhibitors. However, a large-scale evaluation of potential complications has not been conducted to date, and the occurrence of these adverse effects is unclear. Aim: The aim of this study was to evaluate the clinical incidence of interstitial lung disease caused by two CDK4/6 inhibitors, abemaciclib and palbociclib, and assess the relationship between each drug and interstitial lung disease. Methods and results: We evaluated the relationship between the CDK4/6 inhibitors (abemaciclib and palbociclib) and interstitial lung disease in clinical practice using data from the Japanese Adverse Drug Event Report (JADER) database and FDA Adverse Event Reporting System (FAERS) to detect adverse event signals with reported odds ratios (RORs). Furthermore, we performed an adverse event-time analysis for each drug using data from the JADER database to examine the time of onset of the adverse events. The analysis of the reports in the JADER database showed that the lower limit of the 95% confidence interval (CI) of ROR for abemaciclib was >1 regardless of age, and a signal was detected. Interstitial lung disease associated with abemaciclib and palbociclib use has been reported, with an average onset period from treatment initiation [median (25th-75th quartile)] of 65.1 [56.0 days (25.3-98.3 days)] and 53.1 days [38.0 days (10.8-76.0 days)], respectively. The analysis of the reports in the FAERS showed that the lower limit of the 95% CI of the ROR for the two drugs was >1, and a signal was detected. Conclusion: Treatment with abemaciclib and palbociclib is associated with a potential complication of interstitial lung disease, regardless of age. |
|||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||||||||
| 主題 | cyclin-dependent kinase | |||||||||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||||||||
| 主題 | database | |||||||||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||||||||
| 主題 | interstitial lung disease | |||||||||||||||||||||||||||||
| 書誌情報 |
en : Cancer Reports 巻 5, 号 1, p. e1402, 発行日 2021-05-03 |
|||||||||||||||||||||||||||||
| 収録物ID | ||||||||||||||||||||||||||||||
| 収録物識別子タイプ | ISSN | |||||||||||||||||||||||||||||
| 収録物識別子 | 25738348 | |||||||||||||||||||||||||||||
| 出版者 | ||||||||||||||||||||||||||||||
| 出版者 | Wiley Periodicals | |||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||
| 権利情報 | ||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||
| 権利情報 | This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. | |||||||||||||||||||||||||||||
| EID | ||||||||||||||||||||||||||||||
| 識別子 | 375759 | |||||||||||||||||||||||||||||
| 識別子タイプ | URI | |||||||||||||||||||||||||||||
| 言語 | ||||||||||||||||||||||||||||||
| 言語 | eng | |||||||||||||||||||||||||||||
